Related Experiment Video
Updated: May 10, 2025
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Peptides targeting RAB11A-FIP2 complex inhibit HPIV3, RSV, and IAV replication as broad-spectrum antivirals
Yanliang Jiang1, Yongliang Zhao1, Jie Deng1
1State Key Laboratory of Virology and Biosafety, Hubei Provincial Research Center for Basic Biological Sciences, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Background:
The cytoskeletal framework plays a critical role in the early stages of human parainfluenza virus type 3 (HPIV3) replication, including viral mRNA synthesis and translation. However, its contribution to later stages of infection, particularly in the context of RNA biology, is not well understood. This study focuses on the role of the cytoskeleton in viral nucleocapsid (vRNP, a ribonucleoprotein complex essential for RNA virus replication) transport, assembly, and budding, and explores the cooperative role of the small GTPase RAB11A and its effector RAB11 family interacting protein 2 (FIP2) in vRNP trafficking. These processes are crucial for respiratory RNA viruses like respiratory syncytial virus (RSV) and influenza A virus (IAV), highlighting the importance of RNA-protein interactions in viral pathogenesis.
Results:
Through the use of cytoskeleton-depolymerizing agents, the study identified actin microfilaments as indispensable for vRNP transport, viral assembly, and viral particle budding. It also revealed the importance of the RAB11A-FIP2 complex in these processes, which are critical for the intracellular trafficking of viral RNA. The development of peptides targeting the RAB11A-FIP2 complex led to the suppression of RAB11A function in infected cells, resulting in vRNP aggregation in the cytoplasm and reduced viral replication. The peptide YT-DRI showed strong broad-spectrum antiviral activity against HPIV3, RSV, and IAV in cellular and animal models and was effective against co-infections in vitro. The antiviral effects of YT-DRI were abolished upon deletion of RAB11A or core components of the RAB11A pathway.
Conclusion:
This work introduces a promising broad-spectrum antiviral strategy for respiratory tract infections by targeting the RAB11A-FIP2 complex, which regulates the transport and assembly of viral RNA. By disrupting this pathway, YT-DRI effectively inhibits the replication of multiple respiratory RNA viruses, including HPIV3, RSV, and IAV.
Insights
A novel peptide, YT-DRI, targets the RAB11A-FIP2 complex to inhibit replication of respiratory RNA viruses like HPIV3, RSV, and IAV by disrupting viral nucleocapsid transport and assembly.
Area of Science:
- Virology
- Cell Biology
- Molecular Biology
Background:
- The cytoskeleton is vital for early human parainfluenza virus type 3 (HPIV3) replication.
- Its role in later stages, including RNA biology, vRNP transport, assembly, and budding, is less understood.
- The small GTPase RAB11A and its effector FIP2 are investigated for their role in vRNP trafficking.
Purpose of the Study:
- To elucidate the cytoskeleton's role in later stages of HPIV3 replication.
- To explore the cooperative function of RAB11A and FIP2 in vRNP trafficking.
- To develop and test a novel antiviral strategy targeting this pathway.
Main Methods:
- Utilized cytoskeleton-depolymerizing agents to assess the cytoskeleton's role.
- Developed peptides targeting the RAB11A-FIP2 complex.
- Evaluated antiviral activity in cellular and animal models, including co-infections.
Main Results:
- Actin microfilaments are essential for vRNP transport, assembly, and budding.
- The RAB11A-FIP2 complex is critical for viral RNA intracellular trafficking.
- The peptide YT-DRI demonstrated broad-spectrum antiviral activity against HPIV3, RSV, and IAV, inhibiting viral replication.
Conclusions:
- Targeting the RAB11A-FIP2 complex offers a promising broad-spectrum antiviral strategy for respiratory RNA viruses.
- The peptide YT-DRI effectively inhibits HPIV3, RSV, and IAV replication by disrupting vRNP transport and assembly.
- This pathway disruption presents a novel therapeutic approach for respiratory tract infections.
Related Concept Videos
01:10Retrovirus Life Cycles
02:28Leaky Scanning